Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways

Jack L. Arbiser(Boston University), Marsha A. Moses(Boston University), Cecilia A. Fernández(Boston University), Neil Ghiso(Boston University), Yihai Cao(Boston University), Nancy Klauber(Boston University), David A. Frank(Boston University), Michael Brownlee(Boston University), Evelyn Flynn(Boston University), Sareh Parangi(Boston University), H. Randolph Byers(Boston University), Judah Folkman(Boston University)
Proceedings of the National Academy of Sciences
February 4, 1997
Cited by 468Open Access

Abstract

The switch from a quiescent tumor to an invasive tumor is accompanied by the acquisition of angiogenic properties. This phenotypic change likely requires a change in the balance of angiogenic stimulators and angiogenic inhibitors. The nature of the angiogenic switch is not known. Here, we show that introduction of activated H-ras into immortalized endothelial cells is capable of activating the angiogenic switch. Angiogenic switching is accompanied by up-regulation of vascular endothelial growth factor and matrix metalloproteinase (MMP) bioactivity and downregulation of tissue inhibitor of MMP. Furthermore, we show that inhibition of phosphatidylinositol-3-kinase leads to partial inhibition of tumor angiogenesis, thus demonstrating that activated H-ras activates tumor angiogenesis through two distinct pathways. Finally, we show evidence for two forms of tumor dormancy.


Related Papers

No related papers found

Powered by citation graph analysis